CA Patent

CA3172638A1 — Solid dispersions of rifaximin for the treatment of overt hepatic encephalopathy

Assigned to Bausch Health Ireland Ltd · Expires 2021-09-30 · 5y expired

What this patent protects

Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of Overt Hepatic Encephalopathy and complications associated with cirrhosis.

USPTO Abstract

Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of Overt Hepatic Encephalopathy and complications associated with cirrhosis.

Drugs covered by this patent

Patent Metadata

Patent number
CA3172638A1
Jurisdiction
CA
Classification
—
Expires
2021-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Bausch Health Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.